Sun Pharma to acquire Pola Pharma

Sun Pharma will acquire Japan based Polo Pharma for around $1 Million to strengthen its presence in dermatology segment across the globe. The company has entered into a definitive agreement to acquire Pola Pharma, which is engaged in research and development, manufacture, sale and distribution of branded and generic products in Japan.

Pola Pharma portfolio mainly comprises dermatology products. It has two manufacturing facilities in Saitama with capabilities to manufacture topical products and injectables. It also has R&D capabilities to develop new technologies and formulations. Pola Pharma is a leading dermatology company and it will help Sun Pharma launch our specialty and generic dermatology products in the Japanese market in future.

Sun Pharma forayed into the Japanese prescription market in 2016, with the acquisition of 14 established prescription brands from Novartis. The size of the Japanese pharmaceutical market is estimated at $84.8 billion, accounting for around 7.5% of the $1.13-trillion global pharmaceutical market.

Cipla to acquire Avenue Therapeutics

Cipla has entered into an agreement to acquire US based specialty Pharma Company Avenue Therapeutics Inc. for $215 Million. This is in line with Cipla strategy of building a specialty drugs pipeline in the US.

Cipla's US subsidiary InvaGen Pharmaceuticals Inc. will make the acquisition in two stages. In the first stage, InvaGen or its affiliates will acquire a 33.3 per cent stake in Avenue's via new shares for around $35 mn (currently expected to be 5,833,333 shares at $6.00 per share).

Avenue is working on the development and commercialization of intravenous Tramadol, an analgesic to treat pain in adults. There is currently no approved intravenous formulation in the US. Avenue is evaluating IV Tramadol in Phase 3 clinical program: a trial in patients following bunionectomy surgery has been completed and a safety study is ongoing. A pivotal Phase 3 trial in patients following abdominoplasty surgery is expected to commence later this year in 2018.

Cipla, which trails only Sun Pharmaceutical Industries Ltd among Indian drug makers by market value, has been streamlining its operations globally, acquiring products and businesses in some regions while also shedding some units to sharpen focus on core areas.

Google buys Apigee

Alphabet Inc.’s Google is buying software company Apigee Group Corp, for roughly $625 Million, the latest move to bolster its offerings to corporate customers. Apigee specializes in Application Programming Interface or APIs – increasingly important software in modern commerce because they serve as the conduit for automated communication between company’s digital systems and their partners and customers.

For example, when a person buys a pair of jeans on a mobile app, that app typically uses an API to send the sale to the retailer’s computers, which in some cases then use other APIs to connect to suppliers and shippers. Or, rather than calling a pharmacy to send a prescription, doctors can now send the order via app that uses an API to connect with the pharmacy.

Apigee customers, which include AT&T Inc., Walgreen Co., and Burberry Group PLC, pay Apigee a fraction of a cent every time they tap the API. Google has been bolstering its pitch to companies to effectively store and run their digital businesses on Google servers with Google services. The search giant is betting this so called enterprise cloud business can be a major revenue driver over the next several years helping to diversify its business from advertising through Google trials rivals Amazon.com Inc. and Microsoft Corp. in that arena.

Apigee recorded revenue of $66.9 Million for the nine months ended April 30, an increase of 34% from the year earlier period. It posted a $32 Million loss. Apigee had more than 300 customers, an increase of 114 customers since the end of the quarter ended in April of 2015.